| Conversion Value | ₹1,096.13 CrBalance Payment |
|---|---|
| Market Cap | ₹19,693.66 CrPharmaceuticals |
| Promoter Holding | 37.39%Post-Conversion |
| P/E TTM | 29.73Sector 44.59 |
| Deal value | ₹1,096.13 Cr |
| Share of market cap | 5.6% |
| Share of annual revenue | 19.5% |
Key highlights
- Allotment of 2.49 crore equity shares to four promoter group members on September 16, 2026
- Balance payment of ₹438.75 per warrant totaling ₹1,096.13 crore for the conversion
- Promoter group equity holding increased to 37.39% from 31.08% prior to the acquisition
- The transaction stems from preferential warrants originally allotted on February 23, 2026
- Total diluted share capital of the company now stands at 27.27 crore equity shares
Details of the Multi-Crore Promoter Infusion
The allotment of 2,49,82,906 equity shares on September 16, 2026, marks the final stage of a warrant conversion process initiated earlier this year. The acquirers, including Mrs. Chigurupati Uma Devi and Mrs.
Priyanka Chigurupati, paid the remaining 75% of the ₹585 issue price per warrant. This individual capital commitment of ₹1,096.13 crore represents approximately 5.6% of the company's current market capitalization. The infusion follows a broader fund-raising strategy approved in December 2025 aimed at raising ₹1,762.50 crore to support long-term growth and research and development initiatives.
Consolidated Promoter Group Holdings
- Dr. Krishna Prasad Chigurupati remains the largest individual holder with 21.85% equity
- Mrs. Chigurupati Uma Devi increased her direct stake to 12.51% post-conversion
- The total promoter group holding now stands at 10.19 crore shares or 37.39% of capital
- Only 17,094 warrants remain outstanding, held by a single non-promoter investor
- Total voting capital of the company has expanded to 27.27 crore shares of ₹1 each
Strategic Expansion and Financial Momentum
This capital injection coincides with a period of high operational activity for Granules India. On October 7, 2026, the company filed a Paragraph IV ANDA for Ruxolitinib Extended-Release Tablets, seeking 180 days of US generic exclusivity. This follows the October 2 incorporation of a Brazilian subsidiary, Triton Farmaceutica do Brasil Ltda.
Financially, the company reported a robust Q1 FY27 with net profits surging 59.77% year-on-year to ₹179.96 crore. Management has maintained a capital expenditure guidance of ₹600 crore for FY27, focusing on product pipeline development and capacity expansion.
| Date | Announcement | Amount |
|---|---|---|
| 07 Oct 2026 | Submitted Paragraph IV ANDA filing for Ruxolitinib Extended-Release Tablets seeking sole first-to-file status and 180 days of US generic exclusivitySource: thehindu.com | – |
| 02 Oct 2026 | Incorporated wholly owned foreign subsidiary Triton Farmaceutica do Brasil Ltda in BrazilSource: scanx.trade | – |
| 21 Jul 2026 | Approved unaudited consolidated financial results for the first quarter ended 30 June 2026 (Q1 FY27)Source: NSE filing | – |
| 06 Jul 2026 | Secured sole first-to-file ANDA status for generic Sodium Oxybate Extended-Release Oral SuspensionSource: granulesindia.com | – |
| 29 Apr 2026 | Approved audited financial results for FY26 and recommended a final dividend of Rs 1.75 per equity shareSource: zerodha.com | – |
| 23 Dec 2025 | Approved raising funds via preferential allotment of convertible warrants and equity sharesSource: BSE filing | ₹1,762.50 Cr |
What to watch next
- Board meeting for Q2 FY27 financial results scheduled for 02 November 2026
- US FDA approval status for Ruxolitinib Extended-Release Tablets following the October filing
- Execution of the ₹600 crore consolidated capital expenditure plan for FY27
- Progress toward the USD 50 million revenue target for the Peptide CDMO segment within three years
| Share price | ₹794.75 |
|---|---|
| Market capitalisation | ₹19,693.66 Cr |
| Revenue (annual) | ₹5,365.64 Cr |
| Net profit (annual) | ₹595.02 Cr |
| Revenue (latest quarter) | ₹1,476.77 Cr+0.42% vs previous quarter |
| Net profit (latest quarter) | ₹179.96 Cr-10.72% vs previous quarter |
| P/E (TTM) | 29.73×Sector 44.59× |
| Promoter holding | 37.39%-0.63% QoQ |
| FII holding | 20.25%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Granules India Ltd announcing the allotment of equity shares upon conversion of warrants to promoter group members. Market figures from a third-party data provider.
Track Granules India live
Get the next Granules India filing on Telegram seconds after it lands. 15 days free.
